Executive dysfunctions impair and levodopa improves articulatory timing in Parkinson‘s disease

Executive dysfunctions impair and levodopa improves articulatory timing in Parkinson‘s disease

This study investigates the effects of executive functions and levodopa on articulatory timing patterns in simple and complex syllable onsets (CV vs. CCV) in Parkinson’s disease (PD). Kinematic speech data (EMA) of 25 individuals with PD in medication-OFF as well as medication-ON condition and 25 he...

Full description

Saved in:

Bibliographic Details
Main Authors:	Elisa Herbig, Doris Mücke, Michael T. Barbe, Tabea Thies
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2025-07-01
Series:	Frontiers in Human Neuroscience
Subjects:	Parkinson’s disease executive dysfunctions speech motor control syllable coordination levodopa electromagnetic articulography
Online Access:	https://www.frontiersin.org/articles/10.3389/fnhum.2025.1580376/full
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Discinesias induzidas por levodopa em 176 pacientes com doença de Parkinson Levodopa-induced dyskinesias in 176 parkisonian patients
by: Maria Sheila G. Rocha, et al.
Published: (1995-12-01)

Working memory in Parkinson's disease patients: clinical features and response to levodopa Memória de trabalho em pacientes com doença de Parkinson: características clínicas e resposta a levodopa
by: Rogério Beato, et al.
Published: (2008-06-01)

Hyponatremia in Parkinson’s Disease: The Impact of Carbidopa-Levodopa Therapy
by: Elizabeth Schumacher, et al.
Published: (2025-06-01)

Russian assimilatory palatalization is incomplete neutralization
by: Alexei Kochetov, et al.
Published: (2024-05-01)

Lingual Movement during Speech Production by a Speaker of Cantonese with Dysarthria-An Electromagnetic Articulographic Study
by: Manwa Lawrence Ng, et al.
Published: (2016-10-01)

Prosody and levodopa in Parkinsons disease
by: Luciana Lemos de Azevedo, et al.
Published: (2013-11-01)

Contribution of dopaminergic polymorphisms to levodopa treatment response and drug concentration in Chinese patients with Parkinson’s disease
by: Xiaoqin He, et al.
Published: (2025-01-01)

Low serum uric acid levels and levodopa-induced dyskinesia in Parkinson's disease
by: Nayron Medeiros Soares, et al.
Published: (2023-01-01)

Diagnostic prediction model for levodopa-induced dyskinesia in Parkinson’s disease
by: Bruno Lopes SANTOS-LOBATO, et al.
Published: (2020-04-01)

Effect of levodopa on interleukin-15 and RANTES circulating levels in patients affected by Parkinson's disease
by: Sebastiano Gangemi, et al.
Published: (2003-01-01)

Experience in using levodopa-benserazide
by: Elena Anatolyevna Katunina, et al.
Published: (2015-10-01)

Efficacy and motor complications of original and generic levodopa in Parkinson&#39;s disease treatment
by: Kasemsap N, et al.
Published: (2016-05-01)

Pain in Parkinson's disease Dor na doença de Parkinson
by: Grace Helena Letro, et al.
Published: (2009-09-01)

Levodopa-induced motor complications associated with benserazide and carbidopa in Parkinson’s disease: a disproportionality analysis of the FAERS database
by: Huaide Qiu, et al.
Published: (2025-03-01)

Symptom improvement in a South Asian patient with Parkinson’s disease treated with immediate- and extended-release carbidopa–levodopa: a case report
by: Gail Reiner, et al.
Published: (2025-07-01)

Quality of life scale in parkinson's disease PDQ-39 - (Brazilian Portuguese version) to assess patients with and without levodopa motor fluctuation Escala para qualidade de vida na doença de Parkinson - PDQ 39 (versão do Português falado no Brasil) como instrumento para avaliação de pacientes com e sem flutuação motora decorrente da levodopa
by: Renata Guzzo Souza, et al.
Published: (2007-09-01)

How to dose extended-release carbidopa-levodopa capsules (IPX203, CREXONT®) in patients with Parkinson’s disease
by: Robert A. Hauser, et al.
Published: (2025-01-01)

Harbinger of storm: influence of Oliver Sacks on levodopa therapy in early 1970s
by: Bruno Lopes dos Santos-Lobato, et al.
Published: (2016-08-01)

Levodopa and pramipexole combination therapy efficacy in Vietnamese patients with Parkinson’s disease: a randomized controlled trial
by: Minh Van Le, et al.
Published: (2024-03-01)

Levodopa induces thyroid function regulation in a patient with thyroid hormone resistance and Parkinson’s disease: a case report
by: Gabriela Rozo-Paz, et al.
Published: (2025-03-01)

How I treat Parkinson's disease
by: Egberto Reis Barbosa, et al.
Published: (2022-08-01)

Inefficacy of Repetitive Transcranial Magnetic Stimulation in Parkinson’s Disease Patients with Levodopa-Induced Dyskinesias: Results from a Pilot Study
by: Alma Medrano-Hernández, et al.
Published: (2025-07-01)

Inhibition of levodopa metabolism to dopamine by honokiol short-chain fatty acid derivatives may enhance therapeutic efficacy in Parkinson’s disease
by: Gang Cheng, et al.
Published: (2025-06-01)

Automatic speech analysis combined with machine learning reliably predicts the motor state in people with Parkinson’s disease
by: Tabea Thies, et al.
Published: (2025-05-01)

Synergistic action of propolis with levodopa in the management of Parkinsonism in Drosophila melanogaster
by: Herbert Izo, Ninsiima, et al.
Published: (2020)

Continuous Dopaminergic Stimulation-Based Levodopa Treatment in Patients with Early to Mid-Stage Parkinson’s Disease: A Systematic Review and Meta-Analysis
by: Rong Tang, et al.
Published: (2025-05-01)

Translational profiling reveals novel gene expression changes in the direct and indirect pathways in a mouse model of levodopa induced dyskinesia
by: Sabika Jafri, et al.
Published: (2025-03-01)

Investigating white matter alterations in Parkinson’s disease using multi-shell free-water DTI and NODDI: insights into neurodegeneration and levodopa effects
by: Maurizio Bergamino, et al.
Published: (2025-07-01)

Bereitschaftspotential preceding eyelid blinks in Parkinson’s disease
by: Isabella Araújo Mota, et al.

USE OF THREE-COMPONENT LEVODOPA (LEVODOPA/CARBIDOPA/ENTACAPONE) TO CORRECT NOCTURNAL SYMPTOMS OF PARKINSON,S DISEASE
by: T. K. Kulua, et al.
Published: (2015-08-01)

Effect of levodopa and clioquinol on antioxidant capacity in Parkinson’s disease rhesus monkeys
by: LI Like, et al.
Published: (2017-05-01)

Tratamento da doença de Parkinson
by: Francisco Cardoso
Published: (1995-03-01)

A case of Frégoli syndrome following 24-hour levodopa-carbidopa intestinal gel infusion in a patient with Parkinson’s disease undergoing STN-DBS
by: Shunsuke Ogata, et al.
Published: (2025-01-01)

Identification of electromyographic patterns of bradykinesia in patients with Parkinson's disease
by: Nikita Kozulin, et al.
Published: (2024-10-01)

Persistence and adherence to levodopa adjunct medications in elderly patients with Parkinson’s disease: a retrospective cohort study using a Japanese claims database
by: Masahiro Nagai, et al.
Published: (2025-04-01)

Specificity and sensibility of 9-Itens Wearing-off Questionnaire in Brazilian Parkinson disease patient sample
by: Jasper Guimarães Santos, et al.
Published: (2014-11-01)

Respiratory changes in Parkinson's disease may be unrelated to dopaminergic dysfunction
by: Luciana Ulhôa Guedes, et al.
Published: (2012-11-01)

Significant relief of parkinsonism and dystonia with levodopa in beta-propeller protein-associated neurodegeneration: a video case report and insights into the WDR45 c.400C>T mutation
by: Wen-Che Li, et al.
Published: (2025-01-01)

An automatic measure for speech intelligibility in dysarthrias—validation across multiple languages and neurological disorders
by: Johannes Tröger, et al.
Published: (2024-07-01)

Corrigendum: An automatic measure for speech intelligibility in dysarthrias—validation across multiple languages and neurological disorders
by: Johannes Tröger, et al.
Published: (2024-11-01)